The GABAergic system contributes to the anxiolytic-like effect of essential oil from Cymbopogon citratus (lemongrass)  by Costa, Celso A. Rodrigues de Almeida et al.
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Ethnopharmacological  relevance:  The  essential  oil (EO)  from  Cymbopogon  citratus  (DC)  Stapf  is  reported
to  have  a  wide  range  of  biological  activities  and  is  widely  used  in traditional  medicine  as  an  infusion  or
decoction.  However,  despite  this  widely  use,  there  are  few  controlled  studies  conﬁrming  its  biological
activity  in central  nervous  system.
Materials  and methods:  The  anxiolytic-like  activity  of  the  EO was  investigated  in light/dark  box  (LDB)
and  marble-burying  test  (MBT)  and  the  antidepressant  activity  was  investigated  in  forced-swimming
test  (FST)  in  mice.  Flumazenil,  a competitive  antagonist  of  benzodiazepine  binding  and  the  selective
5-HT1A receptor  antagonist  WAY100635  was  used  in  experimental  procedures  to  determine  the  action
mechanism  of EO.  To  exclude  any  false  positive  results  in  experimental  procedures,  mice were submitted
to the  rota-rod  test. We  also  quantiﬁed  some  neurotransmitters  at speciﬁc  brain  regions  after  EO oral
acute  treatment.
Results:  The  present  work  found  anxiolytic-like  activity  of the  EO at  the  dose  of  10  mg/kg  in a  LDB.
Flumazenil,  but  not  WAY100635,  was  able  to  reverse  the  effect  of the EO in the  LDB,  indicating  that
the  EO  activity  occurs  via  the  GABAA receptor–benzodiazepine  complex.  Only  at higher doses  did  the
EO  potentiate  diethyl-ether-induced  sleeping  time  in  mice.  In the  FST  and  MBT,  EO showed  no  effect.
Finally,  the increase  in  time  spent  in the  light  chamber,  demonstrated  by  concomitant  treatment  with
ineffective  doses  of  diazepam  (DZP)  and  the  EO,  revealed  a  synergistic  effect  of  the  two  compounds.  The
lack of  activity  after  long-term  treatment  in  the  LDB  test  might  be  related  to  tolerance  induction,  even in
the  DZP-treated  group.  Furthermore,  there  were  no  signiﬁcant  differences  between  groups  after  either
acute or  repeated  treatments  with  the EO in the  rota-rod  test.  Neurochemical  evaluation  showed  no
amendments  in  neurotransmitter  levels  evaluated  in  cortex,  striatum,  pons,  and  hypothalamus.
Conclusions:  The  results  corroborate  the  use  of  Cymbopogon  citratus  in folk  medicine  and  suggest  that  the
s  EO  i
 anxiolytic-like  effect  of  it
. Introduction
Anxiety and depressive disorders are the most common men-
al illnesses in the world and a prominent health care problem
Herrera-Ruiz et al., 2006; Yu et al., 2007). The World Health Orga-
ization (WHO) estimates that the prevalence of these diseases
anges from 0.1 to 16.9% (Demyttenaere et al., 2004). Benzodi-
zepines are the major class of compounds used to treat generalized
nxiety disorder and acute anxiety states (Rickels and Schweizer,
997; Rupprecht et al., 2006). However, these compounds have
 number of undesirable effects such as sedation, muscle relax-
tion, amnesia, dependence and tolerance (Rickels and Schweizer,
∗ Corresponding author. Tel.: +55 14 3811 6253; fax: +55 14 3815 3744.
E-mail address: mcosta@ibb.unesp.br (M.  Costa).
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Open access under the Elsevier OA license. s  mediated  by  the  GABAA receptor–benzodiazepine  complex.
© 2011 Elsevier Ireland Ltd. 
1997; Reynolds, 2008). Therefore, the search for new therapeutic
agents continues, and medicinal plants have emerged as a crucial
source for the development of drugs to treat neurological disor-
ders and play an important role for patients who  respond poorly to
conventional treatments (Carlini, 2003; Herrera-Ruiz et al., 2006).
Cymbopogon citratus (DC) Stapf (Poaceae), commonly known as
lemongrass, is widely used in traditional medicine as an infusion
or decoction for treating nervous disturbances (Carlini et al., 1986).
In Mexico, Cymbopogon citratus is used as a sedative (Tortoriello
and Romero, 1992), and in Brazil, an infusion or the cold juice of
the leaves has been employed as a sedative and analgesic (Hiruma-
Lima et al., 2002). An antinociceptive effect of Cymbopogon citratus
Open access under the Elsevier OA license.has been detected in the rodent hot plate test, an experimental
procedure related to central activity (Viana et al., 2000). In the
previous work (Costa et al., 2006; Blanco et al., 2009), we have
demonstrated that acute treatment with the essential oil (EO) from
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ymbopogon citratus is effective against generalized anxiety disor-
er and epilepsy in experimental procedures in mice.
In the current study, we investigated the effect of the EO after
ong-term treatment and the putative synergistic effect of the EO
nd diazepam (DZP), a classic anxiolytic drug. We  administered
epeated dosages, instead of a single dosage, to mimic  human
rug regimens and to allow for reductions in individual dosages.
o better characterize its central nervous system activity, the EO
as also evaluated in different experimental procedures related
o depressive and obsessive-compulsive disorders, thus comple-
enting the anxiolytic and sedative/hypnotic protocols. Finally, the
echanism of action of the EO was investigated through blockade
f the GABAergic or serotonergic neurotransmission systems. In
his manner, we sought to elucidate the pharmacological activity
f the EO from Cymbopogon citratus in order to validate its popular
se as an anxiolytic or adjuvant drug in combination with classic
rugs such as benzodiazepines; such a combination could repre-
ent a novel approach for the treatment of anxiety. Regarding that
O compounds are present in moderate amounts of the tea used by
opulation, the development of an EO-based drug would be better
ontrolled and standardized.
. Materials and methods
.1. Plant material
Plant seedlings of specimens from the garden of medicinal
lants (Lageado Farm, UNESP) were cultivated at the Institute
f Biosciences. The plant was identiﬁed in the BOTU Herbarium,
epartment of Botany, UNESP, where a voucher specimen (#23031)
ad been deposited. Leaves of Cymbopogon citratus were collected
etween May  and June of 2008 and immediately processed to
btain the EO.
.2. Essential oil extraction and phytochemical analysis
Fresh leaves were processed with a Clevenger apparatus, and
he EO was obtained by hydrodistillation, protected against light
nd heat, and stored until behavioral assays. Previously, the EO was
nalyzed by gas chromatography coupled with mass spectrometry
GC/MS) as described (Blanco et al., 2009).
Thin layer chromatography (TLC) of EO and decoction was per-
ormed on Silica gel 60 (250 m,  10 cm × 20 cm,  Sigma–Aldrich®
lates) according to previously described methodology (Akisue
t al., 1996). Plates were developed by using a mobile phase
omposed of toluene:ethyl acetate (93:7, v/v). Standards (citral,
-myrcene, and geraniol) were spotted together with plant prepa-
ations under the same conditions and Rf values were used for
onﬁrmation of their chemical identity. Cymbopogon citratus EO,
tandards, and decoction were dissolved in dichloromethane. After
lution, plates were dried, sprayed with anisaldehyde–sulfuric acid
r vanillin–sulfuric acid reagents and heated at 110 ◦C for visual-
zation. All solvents employed for TLC were of analytical grade.
.3. Animals
All experiments were conducted in accordance with the Ethical
rinciples in Animal Research adopted by the Brazilian College of
nimal Experimentation (COBEA) and were approved by the Bio-
ciences Institute – Ethics Committee for Animal Research (CEEA).
dult Swiss male mice (30 days old) from the colony at the UNESP
entral Animal House were used in all experiments after a one-
eek adaptation period at the Animal House of the Department of
harmacology. Thus, the animals used were approximately 40–45
ays old. The animals were maintained under controlled envi-
onmental conditions of temperature (21 ± 2 ◦C) and light (12/12armacology 137 (2011) 828– 836 829
light/dark cycle) with food and water ad libitum until 2 h prior to
the experimental procedures.
2.4. Drugs
Diazepam (DZP, Germed – EMS, Brazil) was used as the standard
anxiolytic and hypnotic drug and imipramine hydrochloride (IM,
Sigma–Aldrich, USA) as the standard antidepressant drug. Flumaze-
nil (FLU, Flumazil® – Cristália, Brazil) was  utilized as a competitive
antagonist of benzodiazepine binding, and WAY100635 (WAY,
Sigma–Aldrich) was  used as a highly selective 5-HT1A antagonist.
For intraperitoneal injections (i.p.), DZP and IM were dissolved in
isotonic saline (SAL – 0.9% NaCl). For oral administration (p.o.),
the EO was dissolved in 0.01% (v/v) polyoxyethylene sorbitan
monooleate (TW – Tween 80®, Sigma–Aldrich) in saline, which was
used to treat control groups. All samples were freshly prepared on
the test day and administered at 10 ml/kg of body weight, except
FLU, which was administered at 20 ml/kg due to the concentration
(0.1 mg/ml) of its commercial form.
2.5. Treatments
In a preliminary experiment, the behavioral data did not dif-
fer among the animals that received the three vehicle solutions –
Tween (TW), saline and water – (data not shown), which justiﬁed
our choice to include only the TW control group data for compar-
ison. For the single treatment, mice were treated 30 min  before
experimental procedures, whereas for long-term treatment (WHO,
1993), animals were treated with the EO for 21 days and exposed
to the experimental procedure 30 min  after the last treatment. For
evaluation of antidepressant activity, mice were treated three times
within the 24 h before the experimental procedure. To address a
possible contribution from the GABAergic system, mice were co-
administered DZP (1 mg/kg, i.p.) or the EO (10 mg/kg, p.o.) 30 min
before the test and then were given FLU (2 mg/kg, i.p.) 15 min  before
testing. To evaluate possible interference from the serotonergic sys-
tem, animals were pretreated with WAY  (0.1 mg/kg, i.p.) and 15 min
afterwards, received the EO (10 mg/kg) or the standard drug DZP
(1 mg/kg); the experimental procedure was carried out 30 min  after
the last drug treatment. To evaluate a putative synergism between
treatments, groups of animals were simultaneously treated with
non-effective doses of DZP (0.25 mg/kg, i.p.) and the EO (2.5 mg/kg,
p.o.).
2.6. Neurochemical evaluation
Animals treated with TW or EO (10 mg/kg) were euthanized
and their brains were rapidly dissected (not more than 3 min  after
extraction) on ice. Brieﬂy, the striatum, hypothalamus, pons, and
frontal cortices were dissected, weighed, and stored in liquid nitro-
gen until the neurochemical analyses.
Following sample collection, tissues were homogenized in 0.1 M
perchloric acid by manual sonication, centrifuged at 10,000 rpm
for 20 min to remove supernatant and stored at −80 ◦C until the
determination of monoamine levels.
Neurotransmitters and their metabolites – dopamine (DA), 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA),
and serotonin (5HT) and 5-hydroxyindoleacetic acid (5HIAA) –
were measured by reverse-phase using an high performance liq-
uid chromatography (HPLC) system (model 6A, Shimadzu, Kyoto,
Japan) with an electrochemical detector as described in detail else-
where (Felicio et al., 1996). Brieﬂy, 20 l samples were loaded
into a sample injector and the mobile phase was  delivered
at a constant rate of 1.2 ml/min. The runtime for each sam-
ple was  15 min  and concentrations of all neurotransmitters and
8 hnoph
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heir metabolites were expressed as nanograms per gram of
issue (ng/g).
.7. Behavioral procedures
Mouse behavior in the forced-swimming test and light/dark box
est was videotaped under white light illumination using a video
amera and a computer. Digital video was subsequently played,
nd behaviors were scored by a highly trained observer who was
lind to treatment condition. In other procedures, the behaviors
ere registered in real time. All experimental procedures occurred
etween 9:00 am and 5:00 pm.
.7.1. Marble-burying test (MBT)
The marble-burying procedure is based on a defensive burying
ehavior that can be elicited in rodents in response to aversive stim-
li such as a shock prod, noxious food or an effective unconditioned
timulus such as glass marbles (Poling et al., 1981; Broekkamp et al.,
986). The mice used in the marble-burying procedure were previ-
usly selected to represent those that exhibit a stable burying score
at least 13 out of 25 marbles) for three consecutive days before the
est (Pultrini et al., 2006). Thirty minutes after treatments with EO
5, 10 or 50 mg/kg), the animals were placed individually in cages
27 long ×16 wide × 13 cm high) with 25 glass marbles uniformly
istributed on a 5-cm layer of sawdust. Each cage was  covered with
 smooth, acrylic, transparent plate with small punctures for venti-
ation. The mice were left in the cages with the marbles for 30 min,
fter which they were removed to count the number of marbles
hat were totally hidden by sawdust.
.7.2. Forced-swimming test (FST)
This test is the most widely used and recognized pharmacolog-
cal model for assessing antidepressant activity (Petit-Demouliere
t al., 2005). This procedure was carried out following a modi-
ed version (Cryan et al., 2002) of the conditions proposed by
orsolt et al. (1977, 1978).  The apparatus consisted of a clear Plex-
glas cylinder (21 cm high × 20.5 cm diameter) ﬁlled with water
23 ± 2 ◦C) to a depth of 13 cm.  Each animal underwent a pre-test
wimming session for 15 min; the pre-tests were carried out 24 h
rior to the 5-min swimming tests. At the end of the swimming
essions, the animals were removed from the water and gently
ried. Mice were treated with EO at 5, 10 or 50 mg/kg according
o the following schedule: the ﬁrst treatment (T1) was  admin-
stered 1 h after ﬁnishing the pre-test session and subsequently
 h (T2) and 30 min  (T3) before the test session. The digital video
ecording of each mouse in the water was evaluated using a time-
ampling technique (Detke et al., 1995) to classify in 10-s bins
he behavioral response into one of these three possible cate-
ories: climbing behavior, deﬁned as upward-directed movements
f the forepaws along the side of the swimming chamber; swim-
ing behavior, deﬁned as movements throughout the swimming
hamber; and immobility time, deﬁned as time during which the
ouse remained ﬂoating in the water and made only the move-
ents necessary to maintain its head above the water (Cryan et al.,
002).
.7.3. Sleep induced by diethyl-ether (SID)
The effectiveness of the EO was measured by its capacity to
educe the latency to sleep and/or to increase the duration of
leep without interfering with hepatic metabolism (Tsuji et al.,
996). Thirty minutes after the treatments with EO (500, 1000
r 1500 mg/kg), animals were induced to sleep by inhalation of
iethyl-ether in a 3-L ﬂask. Each mouse was placed individually in a
ylindrical glass chamber saturated for 20 min  with vapor delivered
rom 5 ml  of diethyl-ether absorbed on a piece of cotton bound in
he coiled cap of the ﬂask. Each mouse was left there for 60 s afterarmacology 137 (2011) 828– 836
loss of its postural reﬂex – sleep latency was  deﬁned as time until
loss of the postural reﬂex – and then was withdrawn and placed in
an individual cage to record the time to recover the postural reﬂex
(sleep duration) (Héllión-Ibarrola et al., 2006).
2.7.4. Light/dark box test (LDB)
The light/dark box (46 long × 27 wide × 30 cm high) was divided
into the typical dimensions of one-third for the dark compartment
with black walls, ﬂoor and roof and two-thirds for the light com-
partment with white walls and ﬂoor and illuminated by a 20-W
ﬂuorescent lamp. The light and dark compartments were connected
by an opening (7.5 cm × 7.5 cm)  located at ﬂoor-level in the cen-
ter of the partition (Crawley and Goodwin, 1980). Thirty minutes
after treatment with EO (5, 10, 50 or 100 mg/kg), each animal was
individually placed in the center of the light compartment, facing
the dark one, and observed for 5 min  after the ﬁrst entry into the
dark compartment. During this period, we  recorded the number of
shuttle crossings (an activity-exploration index), number of rear-
ings and the time spent in the light compartment, which is the most
consistent and useful measure for assessing anxiolytic-like activity.
This parameter provides consistent dose–effect results for anxi-
olytic drugs including benzodiazepines, 5-HT1A receptor agonists
or 5-HT3 receptor antagonists (Young and Johnson, 1991; Bourin
and Hascoët, 2003).
2.7.5. Rota-rod test (RRT)
The rota-rod procedure was described by Dunham and Miya
(1956) and is suitable for detecting motor impairment due to phar-
macological agents such as skeletal muscle relaxants or central
nervous system depressants. The apparatus consisted of a non-
slippery plastic rod, 3.0 cm in diameter and 50 cm in length, rotating
at 5 rpm at a height of 25 cm.  Immediately after the LDB, each mouse
was  placed on the apparatus to register the total time it performed
on the rotating bar in three successive trials totalling 1 min. To avoid
a bias on account of inability not related to drug treatment, one day
prior to testing animals were evaluated, using the same conditions
as those in the test, to select those that had the ability to walk on
the bar.
2.8. Statistical analysis
Quantitative data from behavioral tests were subjected to
Kruskal–Wallis non-parametric variance analysis, followed by the
Mann–Whitney test when appropriate. Proportions in the RRT were
compared by Fisher’s exact test. Neurochemical data were analyzed
by unpaired t-test. All statistical analysis was  made using GraphPad
InStat® version 3.02. Contrasts were made between the treated and
TW (vehicle) groups, and differences were considered statistically
signiﬁcant when p ≤ 0.05.
3. Results
3.1. Essential oil composition
The chromatographic analysis revealed spots with similar qual-
itatively migration patterns. It is possible to observe the presence
of the three major compounds (standards) in both Cymbopogon
citratus EO and decoction, through TLC (Supplementary data).
The main EO compounds were identiﬁed by the retention time
and retention index as monoterpene citral (71.29%), a mixture of
the stereoisomers geranial and neral, or -myrcene (16.5%). Other
compounds detected in the EO include geraniol (1.28%), 6-methyl-
5-hepten-2-ona (0.64%), and undecan-2-one (0.29%), as detailed in
Bidinotto et al. (2010).
hnopharmacology 137 (2011) 828– 836 831
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.2. Neurochemical evaluation
The acute treatment with lemongrass EO did not result in neu-
otransmitters and it metabolites changes (DA, DOPAC, HVA, 5HT,
nd 5HIAA) evaluated in cortex, striatum, pons and hypothalamus
Table 1).
.3. Effect of the EO on the forced-swimming test (FST) and
arble-burying test (MBT)
The EO administered at 5, 10 or 50 mg/kg was unable to mod-
fy parameters evaluated in the FST or MBT, as shown in Table 2.
mipramine, the standard drug in both experimental procedures,
igniﬁcantly decreased the number of immobility events and con-
omitantly augmented the number of climbing and swimming
vents during the FST while also reducing the number of marbles
uried in the MBT.
.4. Effect of the EO on diethyl ether-induced sleep
The EO signiﬁcantly decreased sleep latency after treatment
t 1000 or 1500 mg/kg and increased sleep duration at the same
oses, as did the standard drug DZP (5 mg/kg). Data are presented
n Table 2.
.5. Anxiolytic-like effect of the EO in the LDB
The results obtained in the LDB test after acute treatment with
he EO (Fig. 1, left panel) reveal a signiﬁcant increase in time spent
n the LDB light chamber after acute administration of the EO at
0 mg/kg when compared to the TW group. A discrete increase in
xploratory parameters (number of transitions between compart-
ents and, especially, rearing) could be observed after treatment
ith either the DZP or the EO. However, neither the DZP nor the
O, administered for 21 days, was able to modify the time spent on
he illuminated side of the LDB.
Additionally, the group that was repeatedly treated with saline
nd that received one treatment with DZP 30 min  before the exper-
mental procedure showed an anxiolytic-like effect analogous to
cute DZP treatment (Fig. 1, right panel). This result validates the
xperimental conditions used in the LDB session and conﬁrms
he absence of an anxiolytic-like effect in mice repeatedly treated
ith DZP. Reductions in the number of rearings and transitions
etween compartments were observed after long-term treatment
ith 100 mg/kg of the EO, which was the same trend observed after
ong-term treatment with DZP (Fig. 1B and C).
.6. The role of GABA or 5-HT neurotransmission on the
nxiolytic-like effect of the EO in the LDB
Experimental sessions to evaluate the interference of ﬂumazenil
FLU) or WAY100635 (WAY) in the acute effect of the EO (10 mg/kg)
r DZP (1 mg/kg) were carried out independently; the results are
resented in Fig. 2. Results from FLU or WAY  alone did not differ
rom those obtained from the TW group, showing no per se effect of
hese blockers on evaluated parameters. Mice treated with DZP or
he EO spent more time in the light chamber, when compared with
he TW group – an effect not observed in mice treated concomi-
antly with FLU, a benzodiazepine antagonist (Fig. 2A, left panel).
owever, concomitant treatment with WAY  not only was unable
o block the effect of DZP, as expected, but also could not block the
ffect of the EO (Fig. 2A, right panel). Neither FLU nor WAY  could
everse the effect of DZP or the EO on the exploratory or motiva-
ional parameters such as the numbers of rearings and transitions
etween chambers (Fig. 2B and C). Ta
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Table 2
Effects of essential oil (EO) from Cymbopogon citratus in the forced-swimming test, marble-burying test and sleep induced by diethyl-ether inhalation.
Forced-swimming test Marble-burying test Sleep induced by diethyl-ether inhalation
Treatment N Immobility Climbing Swimming Treatment N Marbles buried Treatment N Latency (s) Sleeping time (s)
TW 7 25 (24–27) 2 (1–2) 4 (3–4) TW 6 23 (19–24) TW 7 47 (44–54) 102 (97–107)
IM  8 18 (16–19)*** 6 (3–7)* 8 (7–11)** IM 6 9 (6–12)* DZP 7 34 (29–49) 177 (169–207)**
EO 5 8 26 (23–28) 2 (1–4) 2 (1–4) EO 5 6 24 (23–24) EO 500 8 38 (34–43) 115 (106–156)
EO  10 8 25 (24–27) 2 (1–2) 3 (1–5) EO 10 6 20 (15–21) EO 1000 7 35 (33–35)** 131 (116–156)*
EO 50 8 26 (25–27) 2 (1–3) 3 (2–3) EO 50 6 21 (14–23) EO 1500 8 29 (25–33)** 146 (123–191)**
TW (Tween); IM (imipramine hydrochloride); DZP (diazepam).
Data are expressed as median and interquartile range (Q1–Q3).
* p ≤ 0.05 in relation to TW group (Kruskal–Wallis followed by Mann–Whitney U-test).
-test).
U-test
3
L
o
T
F
l
d** p ≤ 0.01 in relation to TW group (Kruskal–Wallis followed by Mann–Whitney U
*** p ≤ 0.001 in relation to TW group (Kruskal–Wallis followed by Mann–Whitney 
.7. Effect of combined administration of DZP and the EO in the
DBThe upper left corner of Fig. 3 displays the observed effect
f DZP treatment at 1.0 mg/kg, the effective dose in the LDB.
hus, mice treated with 0.25 mg/kg of DZP or with 2.5 mg/kg
ig. 1. Median and interquartile range (Q1–Q3) of time (in seconds) spent in the illum
ight/dark box after acute or long-term treatment with essential oil (EO) from Cymbopo
iazepam, 1 mg/kg (i.p.). N = 6–8 animals per group. *p ≤ 0.05, **p ≤ 0.01 in relation to TW).
of the EO did not spend more time than the TW group on the
illuminated side of the apparatus, the main anxiety parameter
in the LDB. The EO at 5.0 mg/kg showed a signiﬁcant but dis-
crete augmentation in this parameter. Furthermore, when mice
were treated with a combination of DZP and the EO, at these
non-effective doses, the anxiolytic-like effect was evident, show-
inated chamber (A), number of transitions (B) and number of rearings (C) in the
gon citratus (p.o.); TW – vehicle, 10 ml/kg (p.o.); SAL – saline, 0.9% (p.o.); DPZ –
 group (Kruskal–Wallis followed by Mann–Whitney U-test).
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Fig. 2. Inﬂuence of ﬂumazenil (FLU, 2.0 mg/kg, i.p.) or WAY100635 (WAY 0.1, mg/kg, i.p.) on the anxiolytic effect of diazepam (DZP, 1 mg/kg, i.p.) or essential oil (EO, 10 mg/kg,
p.o.),  expressed as the median and interquartile range (Q1–Q3) of time (in seconds) spent in the illuminated chamber (A), number of transitions (B) and number of rearings
(C)  in the light/dark box; TW – vehicle, 10 ml/kg (p.o.). N = 6–9 animals per group. *p ≤ 0.05, **p ≤ 0.01 in relation to TW group (Kruskal–Wallis followed by Mann–Whitney
U-test).
Fig. 3. Effect of co-administration of essential oil (EO – 2.5 or 5.0 mg/kg, p.o.) 30 min  after an ineffective dose of diazepam (DZP – 0.25 mg/kg, i.p.) treatment, expressed as the
median  and interquartile range (Q1–Q3) of time (in seconds) spent in the illuminated chamber of the light/dark box. TW – vehicle, 10 ml/kg (p.o.). The small ﬁgure embedded,
upper  left corner, represents the observed effect after DZP treatment at 1 mg/kg under the same experimental conditions. N = 6–9 animals per group. **p ≤ 0.01 in relation to
TW  group; #p ≤ 0.05 in relation to EO 5.0 mg/kg group; p ≤ 0.05 in relation to EO 2.5 mg/kg group; +p ≤ 0.05 in relation to DZP 0.25 mg/kg group (Kruskal–Wallis followed
by  Mann–Whitney U-test).
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Table 3
Effects of treatments of essential oil (EO) on motor coordination evaluated by the
rota-rod test.
Treatment Motor impairment
Acute Repeated dosages
TW 1/6 1/6
DZP 1 mg/kg 0/5 0/6
EO 1 mg/kg Not evaluated 0/6
EO  10 mg/kg 0/5 0/7
EO  100 mg/kg Not evaluated 1/7
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tW (Tween); DZP (diazepam).
esults are expressed as the fraction of total animals in each experimental group
hat  were unable to perform the test. Fisher’s exact test.
ng the mutual potentiation of action between the EO and DZP
Fig. 3).
.8. Effect of the EO and DZP on the rota-rod test
The rota-rod test was carried out to measure locomotor impair-
ent in mice treated acutely or repeatedly with DZP or the EO. The
esults, presented in Table 3, include the number of disabled mice
n relation to the total number of treated animals in each experi-
ental group. The disabled mice, deﬁned as those that could not
tay on the rotating bar in a maximum of three attempts at 5 rpm
or 1 min, did not differ statistically from the TW group, suggesting
n absence of treatment-induced motor impairment.
. Discussion
The already considerable attention directed at the use of nat-
ral essential oils from plants is continuing to increase. The
idespread uses of these medicinal oils for bactericidal, antipar-
sitic, insecticidal and medicinal applications are examples of their
harmaceutical use (Bakkali et al., 2008; Fandohan et al., 2008).
Despite the frequent use of Cymbopogon citratus (lemongrass) in
raditional medicine, there are few controlled studies conﬁrming
ts biological activity. According to a review of herbal remedies for
nxiety (Ernst, 2006), there has been only one placebo-controlled
tudy on Brazilian lemongrass tea, conducted by Leite et al. (1986).
ecently, our laboratory demonstrated the anxiolytic-like activity
f the EO from Cymbopogon citratus in experimental models of gen-
ralized anxiety disorder and epilepsy (Costa et al., 2006; Blanco
t al., 2009) at 500 and 1000 mg/kg.
The observation in mice of antinociceptive activity of the EO
rom Cymbopogon citratus at the dose of 25 mg/kg (Viana et al.,
000) and an anticonvulsant effect of the EO from Cymbopogon win-
erianus (Quintans-Júnior et al., 2008) at doses below 400 mg/kg
ncouraged us to evaluate the anxiolytic activity of lower doses of
he EO from Cymbopogon citratus. This approach showed positive
esults in anxiety-related parameters in the LDB, in which EO was
ctive at 10 mg/kg. The biphasic dose–response (U-shaped) curve
bserved in the experiment is similar to the curves extensively
tudied by Calabrese and Baldwin (2003).  This is an example of
he dose–response relation noticeable in the ﬁeld of neuroscience,
specially in pre-clinical screening tests for central nervous system
herapeutic agents (Carvalho-Freitas and Costa, 2002; Calabrese,
008).
The anxiolytic effect of benzodiazepines is due to their binding
o GABAA receptor at a site distinct from the GABA binding site
Whiting, 2003). To determine whether the anxiolytic-like effect
f the EO in the LDB occurs through the GABAergic system, mice
reated with the EO or DZP were co-administered FLU, a ben-
odiazepine GABAA site antagonist. This procedure reversed the
nxiolytic-like activity of not only the standard drug DZP but also
he EO (Fig. 2). The ability of FLU, a speciﬁc GABAA receptor antag-armacology 137 (2011) 828– 836
onist, to antagonize the anxiolytic-like activity of the EO strongly
suggests, for the ﬁrst time, a role of this receptor complex in medi-
ating EO activity. Furthermore, according to Silva et al. (2010) the
EO from Cymbopogon citratus administered i.p. had anticonvulsant
effect, by intraperitoneal route, which was blocked by the pretreat-
ment with ﬂumazenil, suggesting and enhancing a possible effect
on the GABAergic neurotransmission system. The authors did not
exclude a possible interference of other systems (e.g., glycinergic)
in such activity.
The neurochemical assessment revealed no alterations in neu-
rotransmission mediated by dopamine and serotonin after acute
oral treatment with EO. It has been suggested that serotonin
could be a central neurotransmitter involved in the modulation of
anxiety and anti-anxiety effects of benzodiazepines, however neu-
rochemical studies on the effects of that class of drugs on brain
serotonin metabolism/or turnover are not very consistent (Batool
and Haleem, 1997). On the other hand, the diazepam seems to alter
levels of dopamine in the nigrostriatum of rats only at doses greater
than those with anxiolytic and anticonvulsant effects (Invernizzi
et al., 1991). Further, the role of mesolimbic DA projections in the
effects of benzodiazepine-site ligands is still unclear (Heikkinen
et al., 2009).
Even over a large range of doses, the EO produced no effect in
the experimental models of obsessive-compulsive disorder (MBT)
and depression (FST). These experimental models are not sensi-
tive to treatment with benzodiazepines but are sensitive to drugs
like imipramine, which is clinically useful for treating obsessive-
compulsive disorder and depression. Therefore, it was  not surpris-
ing that the EO activity was not disrupted by previous exposure
to the selective 5-HT1A antagonist WAY100635. In our experi-
ence, WAY  at 0.1 mg/kg is able to block the activity of imipramine
(30 mg/kg) in the FST (data not shown). In this manner, the WAY
and EO results corroborate the hypothesis that the anxiolytic-like
activity of the EO is mediated by the GABAergic system.
When doses of DZP (0.25 mg/kg) and the EO (2.5 mg/kg) that
were ineffective per se were co-administered, they had a synergistic
effect on each other. In other words, mice treated with DZP and
the EO at their respective ineffective doses showed a signiﬁcant
increase in time spent in the LDB light chamber. In addition, mice
treated with effective doses of the EO (5.0 mg/kg) and DZP showed
a signiﬁcantly elevated light-chamber duration, when compared to
the EO 5.0 mg/kg alone or with DZP (Fig. 3).
After a single treatment with the EO, mice showed a signiﬁcant
increase in LDB parameters, in contrast to long-term treatment,
either with the EO or with the DZP, which produced no such
increases (Fig. 1). In this procedure, only the animals repeatedly
treated with saline that received DZP 30 min  before the experimen-
tal procedure showed signiﬁcant differences on the LDB anxiety
parameters. Long-term treatment with the EO at 100 mg/kg pro-
duced a behavioral proﬁle similar to that observed with DZP in
the same conditions, with statistical signiﬁcance in reducing the
number of rearings and transitions between black and white com-
partments, without observable effects on motor coordination in the
rota-rod test (Table 3). The reduction in efﬁcacy after long-term
treatment with DZP, and perhaps with the EO, could be due to the
development of tolerance (Reynolds, 2008), as already described
in mice after two  weeks of continuous DZP use (Flaishon et al.,
2003) and which is an EO hypothesis also assessed in other species
(Pultrini et al., 2006).
The EO was effective over a wide dose range. Its sedative effects
reﬂected in the sleep induction studies were achieved at doses
that are 100-fold higher than those found effective in the LDB. In
the experimental procedure involving ether-induced sleeping time,
only at 1500 mg/kg did the EO decrease the latency to sleep and
increase the sleeping time, which proved to be a speciﬁc central
nervous system effect. According to Tsuji et al. (1996),  this effect is
hnoph
n
a
d
a
m
o
r
A
t
(
a
t
s
e
r
d
c
t
e
t
e
f
e
m
m
r
c
f
c
i
T
a
n
p
a
M
w
o
T
a
h
f
d
C
R
A
n
d
C
a
d
A
BC.A.R.A. Costa et al. / Journal of Et
ot related to a pharmacokinetic interaction with hepatic enzymes,
 recognized limitation of barbiturate-induced sleeping time. The
ecrease in spontaneous motor activity (after long-term treatment)
nd potentiation of ether-induced sleeping time (after acute treat-
ent at higher doses) strongly suggest central depressant activity
f the EO.
To exclude any false positive results in experimental procedures
elated to anxiety disorders, mice underwent the rota-rod test.
ll animals treated with different EO doses after acute or long-
erm treatment showed no impairment of the locomotor system
Table 3), thus conﬁrming that the EO from Cymbopogon citratus is
nxiolytic in rodents without any motor impairment.
The absence of toxicity signals or symptoms in mice, whether
reated acutely or repeatedly, at the doses used in the present study
hows the relative safety of the EO. The absence of a deleterious
ffect on the morphological structure of the stomach or liver in
ats treated sub-acutely with doses up to 1500 mg/kg has been
escribed previously (Fandohan et al., 2008). However, the major
ompound in the EO from Cymbopogon citratus induced maternal
oxicity in pregnant rats at doses higher than 125 mg/kg (Nogueira
t al., 1995). This observation conﬁrms that acute toxicity data limit
he pre-clinical applications of the EO because a cumulative toxic
ffect does occur even at very low doses (Mabeku et al., 2007), rein-
orcing the importance of complementary toxicological studies to
valuate the safety of the EO as a complementary therapy in folk
edicine.
Finally, essential oils are complex mixtures of numerous
olecules. The major compounds of the EO from Cymbopogon cit-
atus were identiﬁed by GC/MS (Bidinotto et al., 2010) as follows:
itral (a mixture of the cis and trans isomers – neral and geranial)
ollowed by myrcene and geraniol. According to Vale et al. (2002),
itral and myrcene were not able to modify parameters of anx-
olytic activity in mice, as evaluated by the elevated plus maze.
hese data reinforce the idea that the major compounds are not
lways responsible for biological activity and that such activity can-
ot always be attributed to only one constituent from the herbal
reparation, according to the concept of a multitargeted approach
s a therapeutic strategy (Wagner and Ulrich-Merzenich, 2009).
oreover, for biological purposes, it is more informative to study
hole oil rather than some of its components because the concept
f synergism appears to be more meaningful (Bakkali et al., 2008).
his possible synergism may  be present also in the decoction, once
 qualitatively similar composition was observed in both EO and
erbal preparation. In conclusion, the data presented hereby rein-
orce the traditional use of Cymbopogon citratus in the folk medicine
ue to its anxiolytic-like properties.
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